# Amodiaquine

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

EMLc | ATC codes: P01BA06

| | |
|---|---|
| **Indication** | Malaria due to Plasmodium vivax ICD11 code: 1F41 |
| **INN** | Amodiaquine |
| **Medicine type** | Chemical agent |
| **List type** | Core |
| **Additional notes** | To be used in combination with artesunate 50 mg |
| **Formulations** | **Oral > Solid:** 153 mg (as hydrochloride) ; 200 mg (as hydrochloride) |
| **EML status history** | First added in 1977 (TRS 615)<br>Removed in 1979 (TRS 641)<br>Added in 1982 (TRS 685)<br>Changed in 1984 (TRS 722)<br>Removed in 1987 (TRS 770)<br>Added in 2003 (TRS 920)<br>Changed in 2007 (TRS 946)<br>Changed in 2007 (TRS 950)<br>Changed in 2011 (TRS 965)<br>Removed in 2025 (TRS 1064) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Amodiaquine |
| **DrugBank** | Amodiaquine |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the removal from the EML and EMLc of single-agent amodiaquine tablets. These formulations were not found registered at stringent regulatory authorities. Fixed-dose combination formulations of amodiaquine and artesunate are preferred and are already included on the Model Lists.